Rana Mckay, Md

This study tests whether combining two drugs, cabozantinib and nivolumab, can slow the growth of prostate cancer that has spread and stopped responding to hormone therapy. About 47 men will receive the treatment. The main goal is to see how long the cancer stays under control.

This study tests whether taking a targeted drug (olaparib) plus hormone therapy for 6 months before prostate removal surgery can eliminate or greatly reduce cancer in men with high-risk prostate cancer and specific gene changes. About 32 men will take the drugs, then have surgery…